Influence of genetic co-factors on the population pharmacokinetic model for clopidogrel and its active thiol metabolite
Open Access
- 15 September 2017
- journal article
- pharmacokinetics and-disposition
- Published by Springer Science and Business Media LLC in European Journal of Clinical Pharmacology
- Vol. 73 (12), 1623-1632
- https://doi.org/10.1007/s00228-017-2334-z
Abstract
No abstract availableKeywords
Funding Information
- Narodowe Centrum Nauki (2014/15/B/NZ7/00869)
- Uniwersytet Medyczny w Poznaniu (PL) (502-14-03306413-09628)
This publication has 47 references indexed in Scilit:
- The CYP2C19*17 variant is not independently associated with clopidogrel responseJournal of Thrombosis and Haemostasis, 2013
- ABCB1 C3435T Polymorphism and Response to Clopidogrel Treatment in Coronary Artery Disease (CAD) Patients: A Meta-AnalysisPLOS ONE, 2012
- Meta-Analysis of Cytochrome P450 2C19 Polymorphism and Risk of Adverse Clinical Outcomes Among Coronary Artery Disease Patients of Different Ethnic Groups Treated With ClopidogrelThe American Journal of Cardiology, 2012
- Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects ModelsThe AAPS Journal, 2011
- Clopidogrel pathwayPharmacogenetics and Genomics, 2010
- Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active MetaboliteDrug Metabolism and Disposition, 2009
- Handling Data Below the Limit of Quantification in Mixed Effect ModelsThe AAPS Journal, 2009
- Cytochrome P-450 Polymorphisms and Response to ClopidogrelThe New England Journal of Medicine, 2009
- Impact of P-glycoprotein on clopidogrel absorptionClinical Pharmacology & Therapeutics, 2006
- A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressantsClinical Pharmacology & Therapeutics, 2006